Anivance AI Corporation

Name

Anivance AI Corporation

Legal name

Anivance AI Corporation

Website

https://anivance.io

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Drug Discovery Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Organ-on-chip technology
• Drug discovery platforms
• Preclinical toxicology testing
• AI drug development
• Inhalation toxicity assessment

Headquarters

HQ city

Hsinchu

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Marketing channels1 record

Core offering

Anivance AI Corporation develops AI-integrated organ-on-chip technology for pharmaceutical drug development and preclinical toxicology testing. Its core product is an Inhalation Lung Organ Chip Platform that combines biological organ modeling with artificial intelligence to simulate human lung responses for inhalation toxicity assessment, supporting both new drug development and environmental toxicology evaluation.

Product overview

Anivance AI is a Taiwanese startup specializing in AI organ chips for drug development. The company's core offering is the Inhalation Lung Organ Chip Platform, which combines organ-on-chip technology with artificial intelligence to provide human-relevant data for pharmaceutical research and toxicology assessment. The platform has been selected for international validation through the FNIH NAMs pilot program.

Differentiator

Problem solved

Functional benefit

Products and services

• Inhalation Lung Organ Chip Platform An AI-powered lung organ chip platform designed for inhalation toxicity assessment in drug development and environmental toxicology evaluation. Uses human data-based organ chips combined with artificial intelligence to simulate lung responses. The platform serves pharmaceutical companies, biotechnology firms, and regulatory agencies conducting toxicology testing and drug safety evaluation.

Quantifiable outcome

• Selected among 4 out of 64 global proposals for FNIH NAMs pilot program

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• Foundation for the National Institutes of Health (FNIH)flagshipStrategic or Co-development PartnerAnivance AI's Inhalation Lung Organ Chip Platform was selected for the FNIH global pilot program for new methodologies, out of 64 global proposals with only 4 ultimately selected. The company became the first from Taiwan selected for the FNIH NAMs pilot in inhalation toxicity assessment, with the platform to be included in international validation frameworks for drug development and environmental toxicology.
• Two Industry Leaders (unspecified)coreStrategic or Co-development PartnerJiu Lang Zhi Yi (Anivance AI) completed seed round financing and partnered with two industry leaders to advance organ chip technology and expand smart healthcare global footprint.
• Hsinchu Science ParkminorOthersAnivance AI participated in Hsinchu Science Park-led programs, including the Singapore SWITCH 2025 exhibition, where the company engaged in ecosystem integration activities and connected with local venture capital and academia.
• Taiwan Tech Arena (TTA) / National Science and Technology Council (NSTC)minorOthersThe company participates in TTA and NSTC programs designed to support Taiwanese deep tech and AI startups in reaching international markets.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Emulate, Inc. Leading commercial organ-on-chip company (Liver-Chip, Lung-Chip, Brain-Chip) serving pharma R&D and toxicology. Direct competitor in the same preclinical organ-chip category, with deeper pharma penetration and broader organ portfolio.
• CN Bio Innovations: Developer of PhysioMimix single- and multi-organ microphysiological systems used for ADME and toxicology studies by pharma. Closely comparable product offering and customer base, with established FDA/NIH engagement.
• Mimetas: Organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models in toxicology and disease modeling. Comparable product category and pharma customer base, with similar AI/predictive-biology ambitions.
• TissUse GmbH: Berlin-based organ-on-chip company developing multi-organ 'human-on-a-chip' platforms for drug development and cosmetics testing. Direct competitor in microphysiological systems with overlapping toxicology use cases.
• Hesperos, Inc. Developer of multi-organ human-on-a-chip systems used for toxicology and efficacy testing, particularly in rare disease and IND-enabling studies. Comparable organ-chip technology targeting the same pharma preclinical workflow.
• InSphero AG: 3D microtissue and organoid platform provider for toxicology and disease modeling serving pharma R&D. Comparable in offering human-relevant in vitro alternatives for preclinical toxicology assessment.
• SynVivo, Inc. Provides microfluidic organ-on-chip platforms (including lung and vascular models) for drug delivery and toxicology studies. Directly comparable microphysiological technology for preclinical research.

Emerging players

• AxoSim, Inc. Specialized in nerve-on-a-chip platforms for neurotoxicology and neuroscience drug development. Comparable technology stack and customer type, though focused on neural applications rather than inhalation.
• NETRI: France-based organ-on-chip company using microfluidic devices with neural and organ models for pharma screening. Comparable technology and customer profile, with narrower organ focus similar to Anivance.

Broad incumbents

• Bico Group (CELLINK): Bioconvergence incumbent offering bioprinters, organ-on-chip, and related lab automation tools. Overlaps with Anivance's organ-chip space but operates at much broader scale across multiple life-science workflows.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anivance AI Corporation